Pulmonary toxicities from targeted therapies: a review - Targeted Oncology
- ️Ganti, Apar Kishor
- ️Fri Nov 11 2011
Cohen MH, Williams GA et al (2003) FDA drug approval summary: gefitinib (ZD 1839) (Iressa®) tablets. Oncologist 8:303–306
Cohen MH et al (2005) FDA drug approval summary: erlotinib (Tarceva®) tablets. Oncologist 10:461–466
O’Brien SG et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994–1004
Druker BJ et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408–2417
Kantarjian H et al (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362:2260–2270
Saglio G et al (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251–2259
Cutsem EV et al (2009) Cetuximab and chemotherapy as initial treatment for colorectal cancer. N Eng J Med 360:1408–1417
Cutsem EV et al (2007) Open-labeled phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658–1664
Motzer R et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449–456
Motzer R et al (2010) Phase III trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116:4256–4265
Fukuoka M, Yano S et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237–2246
Kris MG, Natale RB et al (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. JAMA 290:2149–2158
Mok TS, Wu YL et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957
Maemondo M, Inoue A et al (2010) Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR. N Engl J Med 362:2380–2388
Cohen MH et al (2003) FDA drug approval summary: gefitinib (ZD1839) (Iressa®) tablets. Oncologist 8:303–306
Ando M, Okamoto I et al (2006) Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 24:2549–2556
Paez JG et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500
Inoue A et al (2003) Severe acute interstitial pneumonia and gefitinib. Lancet 361:137–139
Dimopoulou I et al (2006) Pulmonary toxicity from novel antineoplastic agents. Ann Onc 17:372–379
Danson S et al (2005) Interstitial lung disease in lung cancer: separating disease progression from treatment effects. Drug Saf 28:103–113
Suzuki M et al (2008) Recurrent gefitinib-induced interstitial lung disease. Intern Med 47:533–536
Herbst RS et al (2005) TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892–5899
Gatzemeier U et al (2007) Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the tarceva lung cancer investigation trial. J Clin Oncol 25:1545–1552
Moore MJ et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of Canada clinical trials group. J Clin Oncol 25:1960–1966
Liu V et al (2007) Pulmonary toxicity associated with erlotinib. Chest 132:1042–1044
Makris D et al (2007) Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer. BMC Cancer 7:150
Geyer CE et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–2743
Bokemeyer C et al (2008) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663–671
Vermorken JB et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Eng J Med 359:1116–1127
Lenz HJ (2007) Management and preparedness for infusion and hypersensitivity reactions. Oncologist 12:601–609
Chua W et al (2009) Cetuximab-associated pulmonary toxicity. Clin Colorectal Cancer 8:118–120
Giusti RM et al (2008) U.S. Food and drug administration approval: panitumumab for epidermal growth factor receptor—expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Clin Cancer Res 14:1296–1302
Slamon DJ et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med 344:783–792
Romond EH et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684
DeMatteo RP et al (2009) Placebo-controlled randomized trial of adjuvant imatinib mesylate following the resection of localized, primary gastrointestinal stromal tumor (GIST). Lancet 373:1097–1104
Demetri GD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472–480
Quintás-Cardama A et al (2007) Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 25:3908–3914
Kantarjian H et al (2007) Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 109:5143–5150
Stephens J et al (2010) The burden of managing pleural effusions in patients with chronic myelogenous leukemia post-imatinib failure: a literature-based economic analysis. Int J Gen Med 3:31–36
Rajda J, Phatak PD (2005) Reversible drug-induced interstitial pneumonitis following imatinib mesylate therapy. Amer J Hem 79:80–81
Yamasawa H et al (2008) Drug-induced pneumonitis associated with imatinib mesylate in a patient with idiopathic pulmonary fibrosis. Respiration 75:350–354
Isshiki I et al (2004) Interstitial pneumonitis during imatinib therapy. Brit J Haemat 125:420
Bergeron A et al (2007) Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Res Crit Care Med 176:814–818
Kaelin W (2004) The von hippel-lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 10:6290S–6295S
Pham P et al (2004) Sirolimus-associated pulmonary toxicity. Clin Transplant 77:1215–1220
Miwa Y et al (2008) Tacrolimus-induced lung injury in a rheumatoid arthritis patient with interstitial pneumonitis. Mod Rheumat 18:208–211
Vandewiele B et al (2010) Diffuse alveolar hemorrhage induced by everolimus. Chest 137:456–459
White D et al (2010) Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Res Crit Care Med 182:396–403
Porta C, et al. (2009) Recommendations for adverse event management in patients with renal cell carcinoma treated with everolimus: safety data from the RECORD-1 Trial: Poster Presented at the 8th International Kidney Cancer Symposium, Chicago, IL, September 25–26, 2009
Hudes G et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Eng J Med 356:2271–2281
Bellmunt J et al (2008) Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Onc 19:1387–1392
Maroto JP et al (2011) Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. J Clin Onc. doi:10.1200/JCO.2010.29.2235
Duran I et al (2006) Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Euro J Cancer 42:1875–1880
Hurwitz H et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Eng J Med 350:2335–2342
Sandler A et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for Non-small-cell lung cancer. N Eng J Med 355:2542–2550
Rini B et al (2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Onc 26:5422–5428
Johnson D et al (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Onc 22:2184–2191
Myung HJ et al (2010) Sorafenib-induced interstitial pneumonitis in a patient with hepatocellular carcinoma: a case report. Gut and Liver 4:543–546
Seidel C et al (2010) Recall pneumonitis during systemic treatment with sunitinib. Ann Oncol 21(10):2119–2120
Leon RJ et al (1994) Rituximab-induced acute pulmonary fibrosis: letters to the editor. Mayo Clin Proc 79:949–950
Burton C et al (2003) Interstitial pneumonitis related to rituximab therapy: to the editor. N Eng J Med 348:2690–2691
Kim KM et al (2008) Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma. Yonsei Med J 49:155–158
Herishanu Y et al (2006) Fatal interstitial pneumonitis related to rituximab-containing regimen. Clin Lymphoma Myeloma 6:407–409
Lim KH et al (2010) Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab. Korean J Intern Med 25:86–92
Swords R et al (2004) Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP). Amer J Hem 77:103–104
Kishi J et al (2009) A case of rituximab-induced interstitial pneumonitis observed in systemic lupus erythematosus. Rheumatology 48:447–448
Lioté H et al (2010) Rituximab-induced lung disease: a systematic literature review. Eur Respir J 35:681–687
Ofatumumab CBD (2010) A novel anti-CD20 monoclonal antibody for the treatement of B-cell malignancies. J Clin Oncol 28:1–6
Osterborg A et al (2008) Ofatumumab (HuMax-CD20), a novel CD20 monoclonal antibody, is an active treatment for patients with CLL refractory to both fludarabine and alemtuzumab or bulky fludarabine-refractory disease: results from the planned interim analysis of an international pivotal trial. Blood 112:126–127
Coiffier B et al (2008) Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1–2 study. Blood 111:1094–1100
Keating MJ et al (2002) Therapeutic role of alemtuzumab (campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99:3554–3561
Lozanski G et al (2004) Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103:3278–3281
Sachdeva A, Matuschak GM (2008) Diffuse alveolar hemorrhage following alemtuzumab. Chest 133:1476–1478
San Miguel JF et al (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906–917
Goy A, et al. (2006) Bortezomib in relapsed or refractory mantle cell lymphoma (MCL): Results of the PINNACLE study. J Clin Oncol. 2006 ASCO Annual Meeting Proceedings PartI. Vol 24, No. 18S (June 20 Supplement):7512
Miyakoshi S et al (2006) Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood 107:3492–3494
Zappasodi P et al (2007) Rapid response to high-dose steroids of severe bortezomib-related pulmonary complications in multiple myeloma. J Clin Oncol 25:3380–3381
Rajkumar SV et al (2005) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the eastern cooperative group. J Clin Oncol 24:431–436
Rajkumar SC et al (2005) Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106:4050–4053
List A et al (2006) Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355:1456–1465
Bennett CL et al (2006) Thalidomide and lenalidomide-associated thromboembolism among patients with cancer. JAMA 296:2558–2560
Onozawa M, et al. (2005) Thalidomide-induced interstitial pneumonitis. J Clin Oncol 2425–2426
Sasaki M et al (2008) Thalidomide may induce interstitial pneumonia preferentially in Japanese patients. Euro J Haem 82:73–74
Feaver AA et al (2006) Thalidomide-induced organizing pneumonia. So Med J 99:1292–1294
Tilluckdharry L et al (2008) Thalidomide-related eosinophilic pneumonia: a case report and brief literature review. Cases Journal 1:1–4
Chen C et al (2009) Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Brit J Haemat 146:164–170